JP2023139070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023139070A5 JP2023139070A5 JP2023114120A JP2023114120A JP2023139070A5 JP 2023139070 A5 JP2023139070 A5 JP 2023139070A5 JP 2023114120 A JP2023114120 A JP 2023114120A JP 2023114120 A JP2023114120 A JP 2023114120A JP 2023139070 A5 JP2023139070 A5 JP 2023139070A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- car
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770239 | 2017-03-31 | ||
| DKPA201770239 | 2017-03-31 | ||
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770542 | 2017-06-30 | ||
| DKPA201770542 | 2017-06-30 | ||
| EPPCT/EP2017/076800 | 2017-10-19 | ||
| PCT/EP2017/076800 WO2018073393A2 (en) | 2016-10-19 | 2017-10-19 | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| PCT/EP2018/058367 WO2018178377A1 (en) | 2017-03-31 | 2018-03-30 | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| JP2020503358A JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503358A Division JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023139070A JP2023139070A (ja) | 2023-10-03 |
| JP2023139070A5 true JP2023139070A5 (enExample) | 2024-04-04 |
| JP7634045B2 JP7634045B2 (ja) | 2025-02-20 |
Family
ID=63674321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503358A Active JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
| JP2023114120A Active JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503358A Active JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11944643B2 (enExample) |
| EP (3) | EP3592379B1 (enExample) |
| JP (2) | JP7314115B2 (enExample) |
| KR (1) | KR102726269B1 (enExample) |
| CN (1) | CN110869046B (enExample) |
| AU (2) | AU2018246378A1 (enExample) |
| BR (1) | BR112019020203A2 (enExample) |
| CA (1) | CA3058268A1 (enExample) |
| DK (1) | DK3592379T3 (enExample) |
| ES (1) | ES2979232T3 (enExample) |
| IL (1) | IL269538B2 (enExample) |
| MX (1) | MX2019011475A (enExample) |
| PT (1) | PT3592379T (enExample) |
| WO (2) | WO2018178378A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| MX2019003888A (es) | 2016-10-05 | 2019-11-28 | Univ Leland Stanford Junior | Compuestos de briostatina y metodos para prepararlos. |
| ES2979232T3 (es) * | 2017-03-31 | 2024-09-25 | Cellectis Sa | Células inmunitarias con receptor de antígeno quimérico anti-CD22 universal |
| CN111954679A (zh) | 2017-10-03 | 2020-11-17 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| CN112888709B (zh) * | 2018-03-30 | 2024-10-29 | 优瑞科生物技术公司 | 标靶cd22的构建体和其用途 |
| KR20210029707A (ko) * | 2018-04-05 | 2021-03-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물 |
| KR20220002859A (ko) * | 2018-12-19 | 2022-01-07 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | T 세포 림프종 및 백혈병에 대한 cd2/5/7 녹-아웃 항-cd2/5/7 키메라 항원 수용체 t 세포의 용도 |
| TWI865517B (zh) | 2019-04-26 | 2024-12-11 | 美商艾洛基因醫療公司 | 抗利妥昔單抗嵌合抗原受體及其用途 |
| MX2021014103A (es) * | 2019-05-21 | 2021-12-15 | Univ Leland Stanford Junior | Compuestos de briostatina para mejorar la inmunoterapia. |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| EP4188954A1 (en) * | 2020-07-31 | 2023-06-07 | Cellectis S.A. | Dual car-t cells |
| CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| CA3207989A1 (en) * | 2021-02-16 | 2022-08-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i?restricted t cell receptors against cd22 |
| KR102829757B1 (ko) * | 2021-11-17 | 2025-07-09 | (주)이노베이션바이오 | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 |
| WO2023122682A1 (en) * | 2021-12-22 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for delivery of therapeutic agents to acceptor cells |
| WO2024153036A1 (zh) * | 2023-01-19 | 2024-07-25 | 武汉昭智生物技术有限公司 | 一种car分子、包含其的细胞或外泌体及它们的应用 |
| WO2025049961A1 (en) * | 2023-09-01 | 2025-03-06 | Cargo Therapeutics, Inc. | Anti-cd22 chimeric antigen receptor (car) therapies |
| WO2025212803A2 (en) * | 2024-04-03 | 2025-10-09 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd22 chimeric antigen receptors |
| CN119775433B (zh) * | 2024-12-09 | 2025-11-28 | 吉林大学第一医院 | 一种细胞膜表达的il-15融合蛋白及其在细胞治疗中的应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| AU2337997A (en) | 1996-03-20 | 1997-10-10 | Arizona Board Of Regents, The | Method of treating cancer using c-26 modified bryostatin |
| AU744445B2 (en) | 1997-04-24 | 2002-02-21 | University Of Washington | Targeted gene modification by parvoviral vectors |
| CA2393026A1 (en) | 1999-11-30 | 2001-06-07 | Paul A. Wender | Bryostatin analogues, synthetic methods and uses |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| WO2008100450A2 (en) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CA2851795C (en) | 2011-10-20 | 2018-11-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126720A2 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| JP6338252B2 (ja) * | 2012-10-24 | 2018-06-06 | アメリカ合衆国 | Ｍ９７１キメラ抗原受容体 |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| CN105765061A (zh) * | 2013-11-22 | 2016-07-13 | 塞勒克提斯公司 | 工程化耐受化疗药物的t-细胞用于免疫治疗的方法 |
| EP3808410A1 (en) * | 2013-12-20 | 2021-04-21 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| US10836998B2 (en) | 2014-02-14 | 2020-11-17 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| WO2015136001A1 (en) * | 2014-03-11 | 2015-09-17 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
| CA2943008C (en) * | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| AU2015248956B2 (en) * | 2014-04-14 | 2020-06-25 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
| US20180002435A1 (en) | 2015-01-26 | 2018-01-04 | Cellectis | mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS |
| AU2016214301B2 (en) * | 2015-02-06 | 2022-05-19 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| WO2016149578A1 (en) * | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-cd22-anti-cd19 chimeric antigen receptors |
| CN115537396A (zh) * | 2015-03-27 | 2022-12-30 | 哈佛学院校长同事会 | 经过修饰的t细胞及其制备和使用方法 |
| WO2016201047A1 (en) | 2015-06-09 | 2016-12-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for improving transplantation |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| CN105958210B (zh) | 2016-05-06 | 2018-10-30 | 中国科学院国家天文台 | Fast望远镜开孔式反射面单元及其开孔方法 |
| CN105968210B (zh) | 2016-05-13 | 2019-05-31 | 深圳生创精准医疗科技有限公司 | 靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途 |
| WO2018007263A1 (en) | 2016-07-06 | 2018-01-11 | Cellectis | Sequential gene editing in primary immune cells |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| ES2979232T3 (es) * | 2017-03-31 | 2024-09-25 | Cellectis Sa | Células inmunitarias con receptor de antígeno quimérico anti-CD22 universal |
| CA3067914A1 (en) * | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| US20230248825A1 (en) * | 2020-07-24 | 2023-08-10 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
-
2018
- 2018-03-30 ES ES18715024T patent/ES2979232T3/es active Active
- 2018-03-30 EP EP18715024.8A patent/EP3592379B1/en active Active
- 2018-03-30 US US16/498,899 patent/US11944643B2/en active Active
- 2018-03-30 EP EP18715025.5A patent/EP3592380B1/en active Active
- 2018-03-30 BR BR112019020203-0A patent/BR112019020203A2/pt unknown
- 2018-03-30 CA CA3058268A patent/CA3058268A1/en active Pending
- 2018-03-30 WO PCT/EP2018/058368 patent/WO2018178378A1/en not_active Ceased
- 2018-03-30 AU AU2018246378A patent/AU2018246378A1/en not_active Abandoned
- 2018-03-30 US US16/498,276 patent/US11690873B2/en active Active
- 2018-03-30 AU AU2018246377A patent/AU2018246377B2/en active Active
- 2018-03-30 JP JP2020503358A patent/JP7314115B2/ja active Active
- 2018-03-30 CN CN201880036267.2A patent/CN110869046B/zh active Active
- 2018-03-30 WO PCT/EP2018/058367 patent/WO2018178377A1/en not_active Ceased
- 2018-03-30 DK DK18715024.8T patent/DK3592379T3/da active
- 2018-03-30 MX MX2019011475A patent/MX2019011475A/es unknown
- 2018-03-30 PT PT187150248T patent/PT3592379T/pt unknown
- 2018-03-30 EP EP24166930.8A patent/EP4414380A3/en active Pending
- 2018-03-30 KR KR1020197032371A patent/KR102726269B1/ko active Active
-
2019
- 2019-09-23 IL IL269538A patent/IL269538B2/en unknown
-
2023
- 2023-07-12 JP JP2023114120A patent/JP7634045B2/ja active Active
- 2023-12-21 US US18/393,322 patent/US12133867B2/en active Active
-
2024
- 2024-09-26 US US18/898,069 patent/US20250026808A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023139070A5 (enExample) | ||
| JP6968389B2 (ja) | Ｂｃｍａに結合するキメラ抗原受容体（ｃａｒ）及びその応用 | |
| CN111527109B (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2020512019A5 (enExample) | ||
| JP2022109953A5 (enExample) | ||
| JP2020096630A5 (enExample) | ||
| JP2024522357A (ja) | クローディン１８．２ｔ細胞－抗原カプラーおよびその使用 | |
| JP2023053328A5 (enExample) | ||
| JP2017537627A5 (enExample) | ||
| KR102316091B1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| CN107406517A (zh) | 包含cd19结合域的嵌合抗原受体(car) | |
| CN105384825A (zh) | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 | |
| JP2017500869A5 (enExample) | ||
| CN110144012A (zh) | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 | |
| CN109789164B (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 | |
| CN110157738B (zh) | 靶向cd19和cd22的工程化免疫细胞及其应用 | |
| JP2023545907A (ja) | 新規共刺激ドメインを含むキメラ抗原受容体及びその使用 | |
| JP2024505955A (ja) | 新型キメラ抗原受容体及びその使用 | |
| CN114249832B (zh) | 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用 | |
| CN110724199A (zh) | Nkg2d car-t细胞及其制备和应用 | |
| CN107663240A (zh) | Mg7，高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 | |
| CN113045657B (zh) | 一种人源化抗人bcma单克隆抗体及其car-t细胞 | |
| AU2020224160A1 (en) | Artificial immunosurveillance chimeric antigen receptor (AI-CAR) and cells expressing the same | |
| JP2025513607A (ja) | Ｃｄ７遺伝子がノックアウトされた操作された免疫細胞及びその用途 | |
| WO2021068108A1 (zh) | Nkg2d car-t细胞及其制备和应用 |